The chief executive officer of Cognito Therapeutics detailed clinical findings from the open-label extension of the phase 2 OVERTURE study presented at the recent Clinical Trials on Alzheimer’s Disease conference. [WATCH TIME: 4 minutes]
Brent Vaughan
Advertisement
Articles by Brent Vaughan
Clinical Potential of Cognito’s Gamma Sensory Stimulation Device in Alzheimer Disease: Brent Vaughan
The chief executive officer of Cognito Therapeutics provided an in-depth overview of the company’s gamma sensory stimulation device, its mechanism of action, and why it serves as a promising therapy for patients with Alzheimer disease. [WATCH TIME: 5 minutes]
Advertisement
Latest Updated Articles
Clinical Potential of Cognito’s Gamma Sensory Stimulation Device in Alzheimer Disease: Brent VaughanPublished: October 27th 2023 | Updated:
Reviewing the Phase 2 OVERTURE Results of Gamma Sensory Stimulation Device: Brent VaughanPublished: October 30th 2023 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Understanding Ocrelizumab’s Impact on Advanced Progressive MS: Insights From Dr. Gavin Giovannoni
2
How Multiple Sclerosis Affects Men
3
Trofinetide Leads to Real-World Improvements in Rett Syndrome Symptoms, LOTUS Study Finds
4
Key Highlights from the 2025 American Neurological Association Annual Meeting
5
